SEC Form 4 · accession 0000899243-16-020304
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Mark J Levin
10% Owner
Robert I Tepper
10% Owner
Third Rock Ventures II, L.P.
10% Owner
Third Rock Ventures GP II, L.P.
10% Owner
TRV GP II, LLC
10% Owner
Period of report
May 16, 2016
Accepted (ET)
May 18, 2016 · 4:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 16, 2016 | S | 850,000 | $31.25 | D | 3,892,916 | D | |
| Common StockF2 | holding | — | — | — | 65,226 | D | ||
| Common StockF3 | holding | — | — | — | 65,226 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares are directly held by Third Rock Ventures II, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP II, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP II, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin, Kevin Starr and Dr. Robert Tepper. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
- F2The shares are directly hold by Dr. Robert Tepper.
- F3The shares are directly held by Mark Levin.